Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?
Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.